Avalyn Pharma (NASDAQ:AVLN) Stock Falls 5.9% - What's Next?

Key Points

• Avalyn Pharma shares fell 5.9% to $25.64 in relatively light trading, well below the company’s 50-day moving average of $31.63.
• Analyst sentiment remains mixed, but the stock carries a “Moderate Buy” consensus and an average price target of $60.00; recent ratings ranged from “sell” to “outperform.”
• Avalyn reported a quarterly loss of $0.98 per share, slightly better than estimates, while institutional investors—including Montanara Capital and Braidwell—recently built significant positions. Its lead candidate is AP01, an inhaled formulation of pirfenidone for pulmonary fibrosis.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s share price dropped 5.9% on Friday. The company traded as low as $25.45 and last traded at $25.64. 67,070 shares changed hands during trading, a decline of 78% from the average session volume of 311,894 shares. The stock had previously closed at $27.25.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Wall Street Zen lowered Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. Weiss Ratings initiated coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They set a "sell (d+)" rating on the stock. Finally, Raymond James Financial initiated coverage on Avalyn Pharma in a research note on Friday, October 2nd. They set an "outperform" rating and a $60.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Price Performance

The company has a market capitalization of $1.15 billion and a P/E ratio of -1.14. The company's fifty day moving average is $31.63. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. On average, equities research analysts predict that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Trading of Avalyn Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVLN. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma in the 2nd quarter worth approximately $1,321,000. Montanova Capital LLC bought a new position in Avalyn Pharma in the 2nd quarter valued at $82,402,000. Braidwell LP acquired a new position in Avalyn Pharma in the second quarter worth $26,382,000. State Street Corp bought a new stake in shares of Avalyn Pharma during the second quarter worth $10,501,000. Finally, Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma in the third quarter valued at $36,000.

About Avalyn Pharma

Avalyn Pharma, Inc NASDAQ: AVLN is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company's research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.